Clinical validation of the tempus xT next-generation targeted oncology sequencing assay

Citations Over TimeTop 10% of 2019 papers

Abstract

We developed and clinically validated a hybrid capture next generation sequencing assay to detect somatic alterations and microsatellite instability in solid tumors and hematologic malignancies. This targeted oncology assay utilizes tumor-normal matched samples for highly accurate somatic alteration calling and whole transcriptome RNA sequencing for unbiased identification of gene fusion events. The assay was validated with a combination of clinical specimens and cell lines, and recorded a sensitivity of 99.1% for single nucleotide variants, 98.1% for indels, 99.9% for gene rearrangements, 98.4% for copy number variations, and 99.9% for microsatellite instability detection. This assay presents a wide array of data for clinical management and clinical trial enrollment while conserving limited tissue.

Related Papers

• → The missing indels: an estimate of indel variation in a human genome and analysis of factors that impede detection(2015)61 cited
• → The pattern of insertion/deletion polymorphism in Arabidopsis thaliana(2008)29 cited
• → Genetic structure and relationships among 11 cattle populations using indel markers(2018)1 cited
• → Deep indel mutagenesis reveals the impact of amino acid insertions and deletions on protein stability and function(2023)18 cited